Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 58, Issue 5, 2003, Pages 371-379

  Gevaert, Philippe ^a   Bachert, C ^a   Holtappels, G ^a   Novo, C P ^a   Van Der Heyden, J ^b   Fransen, L ^c   Depraetere, S ^c   Walter, H ^c   Van Cauwenberge, P ^a   Tavernier, J ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c INNOGENETICS   (Belgium)

Author keywords

Asthma; Enzyme linked immunosorbent assay; Eosinophils; Interleukin 5 receptor alpha; Nasal polyps; Polymerase chain reaction

Indexed keywords

INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 5 RECEPTOR ALPHA; INTERLEUKIN 5 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; ASTHMA; BLOOD ANALYSIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MEMBRANE BINDING; NOSE POLYP; NOSE SECRETION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REACTION OPTIMIZATION; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; TRANSCRIPTION REGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTHMA; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILS; FEMALE; HUMANS; INTERLEUKIN-5; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL POLYPS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 0037514567     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2003.00110.x     Document Type: Article

References (23)

1. LECKIE MJ, TEN BRINKE A, KHAN J, DIAMANT Z, O'CONNOR BJ, WALLS CM, MATHUR AK, COWLEY HC, CHUNG KF, DJUKANOVIC R, HANSEL TT, HOLGATE ST, STERK PJ, BARNES PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
2. BACHERT C, WAGENMANN M, HAUSER U, RUDACK C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997;99:837-842.
3. HAMILOS DL, LEUNG DY, HUSTON DP, KAMIL A, WOOD R, HAMID Q. GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin Exp Allergy 1998;28:1145-1152.
4. BACHERT C, GEVAERT P, HOLTAPPELS G, CUVELIER C, VAN CAUWENBERGE P. Nasal polyposis: from cytokines to growth. Am J Rhinol 2000;14:279-290.
5. BACHERT C, GEVAERT P, HOLTAPPELS G, JOHANSSON SG, VAN CAUWENBERGE P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001;107:607-614.
6. TAVERNIER J, TUYPENS T, PLAETINCK G, VERHEE A, FIERS W, DEVOS R. Molecular basis of the membrane-anchored and two SOL isoforms of the human interleukin 5 receptor alpha subunit. Proc Natl Acad Sci USA 1992;89:7041-7045.
7. TAVERNIER J, TUYPENS T, VERHEE A, PLAETINCK G, DEVOS R, VAN DER HEYDEN J, GUISEZ Y, OEFNER C. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proc Natl Acad Sci USA 1995;92:5194-5198.
8. TAVERNIER J, CORNELIS S, DEVOS R, GUISEZ Y, PLAETINCK G, VAN DER HEYDEN J. Structure/function analysis of human interleukin 5 and its receptor. Agents Actions Suppl 1995;46:23-34.
9. RIZZO CA, YANG R, GREENFEDER S, EGAN RW, PAUWELS RA, HEY JA. The IL-5 receptor on human bronchus selectively primes for hyperresponsiveness. J Allergy Clin Immunol 2002;109:404-409.
10. HAKONARSON H, MASKERI N, CARTER C, CHUANG S, GRUNSTEIN MM. Autocrine interaction between IL-5 and IL-1 beta mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. J Clin Invest 1999;104:657-667.
11. TAVERNIER J, DEVOS R, CORNELIS S, TUYPENS T, VAN DER HEYDEN J, FIERS W, PLAETINCK G. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991;66:1175-1184.
12. TAVERNIER J, VAN DER HEYDEN J, VERHEE A, BRUSSELLE G, VAN OSTADE X, VANDEKERCKHOVE J, NORTH J, RANKIN SM, KAY AB, ROBINSON DS. Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit. Blood 2000;95:1600-1607.
13. CAMERON L, CHRISTODOULOPOULOS P, LAVIGNE F, NAKAMURA Y, EIDELMAN D, MCEUEN A, WALLS A, TAVERNIER J, MINSHALL E, MOQBEL R, HAMID Q. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J Immunol 2000;164:1538-1545.
14. VANDESOMPELE J, DE PRETER K, PATTYN F, POPPE B, VAN ROY N, DE PAEPE A, SPELEMAN F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:34.
15. KIKUCHI Y, MIGITA M, TAKAKI S, TOMINAGA A, TAKATSU K. Biochemical and functional characterization of soluble form of IL-5 receptor alpha (sIL-5R alpha). Development of ELISA system for detection of sIL-5R alpha. J Immunol Methods 1994;167:289-298.
16. MURATA Y, TAKAKI S, MIGITA M, KIKUCHI Y, TOMINAGA A, TAKATSU K. Molecular cloning and expression of the human interleukin 5 receptor. J Exp Med 1992;175:341-351.
17. TUYPENS T, PLAETINCK G, BAKER E, SUTHERLAND G, BRUSSELLE G, FIERS W, DEVOS R, TAVERNIER J. Organization and chromosomal localization of the human interleukin 5 receptor alpha-chain gene. Eur Cytokine Netw 1992;3:451-459.
18. MONAHAN J, SIEGEL N, KEITH R, CAPARON M, CHRISTINE L, COMPTON R, CUSIK S, HIRSCH J, HUYNH M, DEVINE C, POLAZZI J, RANGWALA S, TSAI B, PORTANOVA J. Attenuation of IL-5-mediated signal transduction, eosinophil survival, and inflammatory mediator release by a soluble human IL-5 receptor. J Immunol 1997;159:4024-4034.
19. MCKINNON M, PAGE K, UINGS IJ, BANKS M, FATTAH D, PROUDFOOT AE, GRABER P, AROD C, FISH R, WELLS TN, SOLARI R. An interleukin 5 mutant distinguishes between two functional responses in human eosinophils. J Exp Med 1997;186:121-129.
20. BLUMCHEN K, KALLINICH T, HAMELMANN E. Interleukin-5: a novel target for asthma therapy. Expert Opin Biol Ther 2001;1:433-453.
21. SIMON HU, YOUSEFI S, SCHRANZ C, SCHAPOWAL A, BACHERT C, BLASER K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902-3908.
22. EGAN RW, ATHWAL D, BODMER MW, CARTER JM, CHAPMAN RW, CHOU CC, COX MA, EMTAGE JS, FERNANDEZ X, GENATT N, INDELICATO SR, JENH CH, KREUTNER W, KUNG TT, MAUSER PJ, MINNICOZZI M, MURGOLO NJ, NARULA SK, PETRO ME, SCHILLING A, SEHRING S, STELTS D, STEPHENS S, TAREMI SS, ZURCHER J. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung 1999;49:779-790.
23. GREENFEDER S, UMLAND SP, CUSS FM, CHAPMAN RW, EGAN RW. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2001;2:71-79.